Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism

(2022) Nanyong Gao et al.   Frontiers in Pharmacology

Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer

(2021) Hayato Yokota et al.   Biology-Basel

Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

(2020) Jing Huang et al.   Scientific Reports

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

(2018) Karthick Vishwanathan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy

(2018) A. Kenneth MacLeod et al.   CLINICAL CANCER RESEARCH

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers

(2017) Karthick Vishwanathan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis

(2017) Tomohiro Tamura et al.   LUNG CANCER

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats

(2017) Osamu Yasumuro et al.   XENOBIOTICA

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

(2016) David Planchard et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non–Small-Cell Lung Cancer

(2015) Hiroyuki Kobayashi et al.   Clinical Lung Cancer

A Limited Sampling Strategy for Estimation of the Area Under the Plasma Concentration–Time Curve of Gefitinib

(2014) Masatomo Miura et al.   THERAPEUTIC DRUG MONITORING

Association of ABCC2 Genotype with Efficacy of First-line FOLFIRI in Japanese Patients with Advanced Colorectal Cancer

(2011) Yuko Akiyama et al.   Drug Metabolism and Pharmacokinetics

Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients

(2011) Masatomo Miura et al.   PHARMACOGENOMICS

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

(2010) Naoto Takahashi et al.   JOURNAL OF HUMAN GENETICS